LONG-TERM EFFICACY AND SAFETY OF RITUXIMAB IN ANCA-ASSOCIATED VASCULITIS: RESULTS FROM A UK TERTIARY REFERRAL CENTRE
Background: Rituximab has been shown in RCTs to be efficacious in AAV. However, there is little published data on long-term safety. The German registry report on 58 patients (mean follow-up 17.5 months) did not report increased infection rates, whereas a recent study of 35 GPA cases from Norway reported that at 48 months 37% of patients had discontinued RTX for hypogammaglobulinaemia or infection. Here we report long-term follow-up of 33 patients with AAV with mean follow-up of 43 (range 1-101) months. Methods: Retrospective case note review of 33 patients with refractory AAV (30 GPA, 2 MPA, 1 EGPA) treated with RTX since 2005.
Results: In 32 patients RTX was initiated for relapse ] and all 32 achieved remission (BVAS ¼ 0). Both 375 mg/m 2 weekly Â4 and 1 g Â2 were used with equal efficacy. In one patient RTX was initiated to maintain remission. The mean cumulative RTX dose was 8.3 g (2-21.4 g) over mean 4 (1-10) courses. Relapses were common in patients without protocolized retreatment, occurring at mean 9.6 (range 5-20) months post RTX. All were successfully retreated. 26 patients are in remission, with 7 currently being treated for relapse. Of the 26 patients in remission, 10 are continuing RTX for maintenance, 6 have completed a 2 year course and have sustained remission, and 5 are in remission following only 1 course. The remaining 5 patients are currently in remission but planned RTX maintenance therapy was stopped due to developing immunodeficiency. Overall, mean IgG levels fell significantly during follow-up, and progressively with repeated treatments, and IgM levels fell more rapidly and are subnormal in 57.6% patients. We previously reported a smaller cohort with shorter follow-up (mean 34 months) in 2011, and infections appeared rare. However, 17 patients now have follow-up more than 36 months and in this group infections are much more common. Background: The vasculitides are a set of rare conditions. The natural history of treated disease has improved with modern immunosuppression but the long term outcome remains unsatisfactory. Our aim is to establish a UK and Ireland registry for all patients with different forms of vasculitis in order to provide comparative outcome data on a large cohort of patients with different ethnic backgrounds. We present cross-sectional data on the first 556 patients. Methods: We recruited patients with a primary diagnosis of systemic vasculitis under regular care of a variety of specialists across the UK and Ireland. The initial focus was on ANCA positive patients only. We developed a software program to enable prospective collection of anonymized clinical data with local storage of patient identifiable information. We recorded details of demographics, diagnosis, clinical manifestations, ANCA status, treatment and mortality.
Results: 556 patients were recruited from 13 centres. The detailed characteristics of this cohort are presented in Table 1 . The median age at diagnosis was 55.2 years (IQR 42.4-65.7) with equal gender distribution. Almost 90% had a white Caucasian background. 85% had a diagnosis of MPA, GPA or EGPA, the remaining 15% were defined as unclassified AAV (2.2%), anti-GBM disease (1.8%), IgA vasculitis (1.8%) and other types of vasculitis (<1% each). 11% of cases were newly diagnosed. , to use to study the development and consequences of damage. Earlier validation studies of the Indian Takayasu Activity Score (ITAS2010) indicated that disease activity in TA was not fully suppressed by current therapy. We examined the hypothesis that continued disease activity drives development of early damage by analysing whether TADS on follow-up correlated with disease activity at initial visit or with other factors. Methods: Initial ITAS2010 and disease extent (DEI.Tak) scores at 1st visit in 39 patients were calculated from information available, although ITAS-A and TADS could only be scored in 36 and 17 patients respectively. All the patients fulfilled ACR criteria for TA. At the last follow-up visit after a mean period of 2.18 years (AE1.75) the patients were re-assessed for activity and damage. Statistical analysis was performed to see if the final damage had any relation with initial ITAS2010, ITAS-A, DEI.Tak or TADS by Pearson's correlation coefficient. A value of P < 0.05 was considered significant. Results: There were 31 females. The mean age was 28.2 AE 9.4 years and the median duration of symptoms was 2 years (IQR 0.75-5 years). At presentation the mean values of ITAS2010, ITAS-A, DEI.Tak and TADS were 12.1 AE 6.1, 13.3 AE 6.0, 12 AE 4.1 and 3.2 AE 3.7 respectively. At follow-up, the mean TADS follow-up (TADSf) in 39 patients was 8.6 AE 3.4. TADSf did not correlate with initial ITAS2010 or ITAS-A but did correlate significantly with DEI.Tak (r 0.4, P < 0.05). Among individual DEI.Tak manifestations, the presence of pulse loss (P < 0.005) or neurologic features (seizure, syncope or stroke) (P < 0.03) predicted more damage. In 30 patients who had disease duration more than 2 years the TADSf was significantly higher (9.3 AE 3.4 vs 6.3 AE 2.7; P < 0.05) as compared with the rest. In 17 patients where base line TADS was available the mean change in TADS (ÁTADS ¼ TADSf-TADS) had a significant negative correlation with initial TADS (r ¼ -0.73; P < 0.05). ÁTADS was significantly less for baseline TADS !5 (2.5 AE 2.3; n ¼ 6) as compared with baseline TADS <5 (7.5 AE 3.1; n ¼ 11; P < 0.01).
Conclusion:
In TA, damage after a mean period of 2 years correlated with initial disease extent but not with activity. The presence of pulse loss and CNS features were associated with more damage at followup visit. The progression of damage was less if baseline damage was higher, suggesting that most of the early damage in TA occurs during the presenting episode. Disclosure statement: The authors have declared no conflicts of interest. Background: The Euro-Lupus low dose cyclophosphamide (CPM) protocol has been validated for use in lupus nephritis patients in randomized controlled trials. Our aim is to assess the efficacy and safety of this low dose CPM therapy in patients with systemic vasculitides. Methods: We retrospectively assessed 26 patients with systemic vasculitis at the Louise Coote lupus Unit at Guy's and St Thomas' Hospital who received low dose CPM induction therapy along with corticosteroids during the last 15 years. All patients fulfilled the ACR/ Chapel Hill classification criteria for GPA/eosinophilic GPA (eGPA) and microscopic polyangiitis (MPA). All patients received 3 pulses of methylprednisolone 500 mg and 6 pulses of CPM infusions 500 mg with mesna fortnightly as induction therapy. Subsequently AZA, MTX or MMF were used as remission maintaining agents. Data regarding inflammatory markers (ESR and CRP), Birmingham Vasculitis Activity Score (BVAS) and Vasculitis Damage Index (VDI) scores were assessed at baseline and after 6, 12, 24, 60, 120 and 180 months. Data on all relapses, organ involvement, duration of remission, corticosteroid requirement were documented. Patients who needed repeat CPM infusions, rituximab and adverse events were also recorded.
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Results: 26 patients (13 males and 13 females) were assessed retrospectively. There were 22 Caucasians, 2 mixed and 2 Asians. The median age of the patients was 54.84. 20 patients had positive ANCA antibodies (15 anti-PR3 and 5 anti-MPO positive). 6 were ANCA negative. The median disease duration prior to induction therapy was 3.12 years. 10 of 26 patients had pulmonary involvement (pulmonary hemorrhages, haemoptysis, cavitating lung lesions, nodules), 9 necrotizing crescentic GN, 1 myocarditis, 13 had neurological manifestations including raised ICP, tentorial and occipital masses, mononeuritis multiplex and orbital granulomas, necrotizing scleritis and otitis media with hearing loss and 1 had bowel ischaemia. Comorbidities were antiphospholipid syndrome, positive lupus anticoagulant, type 2 diabetes mellitus, tuberculosis and sleep apnoea. All 334 
